Charles River Laboratories International, Inc. shows a moderate fundamental position with some room for improvement. The healthcare sector it operates in is competitive, and the company provides essential services in drug discovery and safety testing. Its diverse segment operations contribute to its overall strength in the market.
The current fundamental scores for CRL indicate a moderate position with key areas needing attention.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 3 |
The historical data suggests consistent performance over the past periods with slight improvements.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2 | 3 | 1 | 1 | 1 | 1 | 3 |
| -- | 0 | 3 | 1 | 1 | 1 | 1 | 3 |
Analysts show a generally positive expectation with a high target of $220 and a consensus around $213.17.
| High | Low | Median | Consensus |
|---|---|---|---|
| $220 | $192 | $217 | $213.17 |
Analyst sentiment leans positively with more Buy recommendations, showing confidence in future performance.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 25 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Charles River Laboratories International, Inc. offers a promising yet cautious investment opportunity. The company's diverse operations in healthcare provide stability and potential growth. However, areas such as return on equity and asset management need improvement. Analyst sentiment remains positive, reflecting confidence in the company's future potential. Investors should consider the competitive landscape and ongoing needs for strategic improvements in financial metrics.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.